340 related articles for article (PubMed ID: 19383911)
21. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
22. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.
Birch AH; Arcand SL; Oros KK; Rahimi K; Watters AK; Provencher D; Greenwood CM; Mes-Masson AM; Tonin PN
PLoS One; 2011; 6(12):e28250. PubMed ID: 22163003
[TBL] [Abstract][Full Text] [Related]
23. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization.
Hauptmann S; Denkert C; Koch I; Petersen S; Schlüns K; Reles A; Dietel M; Petersen I
Hum Pathol; 2002 Jun; 33(6):632-41. PubMed ID: 12152163
[TBL] [Abstract][Full Text] [Related]
24. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
25. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
26. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
Engler DA; Gupta S; Growdon WB; Drapkin RI; Nitta M; Sergent PA; Allred SF; Gross J; Deavers MT; Kuo WL; Karlan BY; Rueda BR; Orsulic S; Gershenson DM; Birrer MJ; Gray JW; Mohapatra G
PLoS One; 2012; 7(2):e30996. PubMed ID: 22355333
[TBL] [Abstract][Full Text] [Related]
27. The molecular pathology of ovarian serous borderline tumors.
Malpica A; Wong KK
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
[TBL] [Abstract][Full Text] [Related]
28. Ovarian Combined Serous Borderline Tumor/Low-grade Serous Carcinoma and Mesonephric-like Lesion: Report of 2 Cases With New Observations.
Nilforoushan N; Liu L; Finkelman BS; Andersen J; Liu Y; James J; Hung CF; Wu TC; Vang R; Xing D
Int J Gynecol Pathol; 2023 Mar; 42(2):182-191. PubMed ID: 35348533
[TBL] [Abstract][Full Text] [Related]
29. Low-grade serous carcinomas of the ovary contain very few point mutations.
Jones S; Wang TL; Kurman RJ; Nakayama K; Velculescu VE; Vogelstein B; Kinzler KW; Papadopoulos N; Shih IeM
J Pathol; 2012 Feb; 226(3):413-20. PubMed ID: 22102435
[TBL] [Abstract][Full Text] [Related]
30. Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
Zhang X; Devins K; Ko EM; Reyes MC; Simpkins F; Drapkin R; Schwartz LE; Yoon JY
Gynecol Oncol; 2021 Jun; 161(3):762-768. PubMed ID: 33773808
[TBL] [Abstract][Full Text] [Related]
31. Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
Van Nieuwenhuysen E; Busschaert P; Laenen A; Moerman P; Han SN; Neven P; Lambrechts D; Vergote I
Neoplasia; 2019 Jun; 21(6):582-590. PubMed ID: 31054497
[TBL] [Abstract][Full Text] [Related]
32. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
[TBL] [Abstract][Full Text] [Related]
33. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas.
Dodson MK; Hartmann LC; Cliby WA; DeLacey KA; Keeney GL; Ritland SR; Su JQ; Podratz KC; Jenkins RB
Cancer Res; 1993 Oct; 53(19):4456-60. PubMed ID: 8402612
[TBL] [Abstract][Full Text] [Related]
34. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.
Kurman RJ
Ann Oncol; 2013 Dec; 24 Suppl 10():x16-21. PubMed ID: 24265397
[TBL] [Abstract][Full Text] [Related]
35. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.
Staebler A; Heselmeyer-Haddad K; Bell K; Riopel M; Perlman E; Ried T; Kurman RJ
Hum Pathol; 2002 Jan; 33(1):47-59. PubMed ID: 11823973
[TBL] [Abstract][Full Text] [Related]
36. Poor survival with wild-type TP53 ovarian cancer?
Wong KK; Izaguirre DI; Kwan SY; King ER; Deavers MT; Sood AK; Mok SC; Gershenson DM
Gynecol Oncol; 2013 Sep; 130(3):565-9. PubMed ID: 23800698
[TBL] [Abstract][Full Text] [Related]
37. Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma.
Shih IeM; Nakayama K; Wu G; Nakayama N; Zhang J; Wang TL
Mod Pathol; 2011 May; 24(5):638-45. PubMed ID: 21240255
[TBL] [Abstract][Full Text] [Related]
38. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
[TBL] [Abstract][Full Text] [Related]
39. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).
Singer G; Shih IeM; Truskinovsky A; Umudum H; Kurman RJ
Int J Gynecol Pathol; 2003 Jan; 22(1):37-41. PubMed ID: 12496696
[TBL] [Abstract][Full Text] [Related]
40. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]